Browse Articles
Discover research articles across all indexed journals
Molecular characterization of some multidrug resistant Candida Auris in egypt
Abstract Candida auris is an emerging multidrug-resistant yeast that causes healthcare-associated and deep-seated infections. Notably, the emergence of this yeast is alarming as it exhibits resistance to azoles, echinocandins, and amphotericin B, which may lead to clinical treatment failure in patients. This study aims to identify and characterize the genetic determinants of antifungal resistance in C. auris among some local clinical isolates to contribute for understanding the molecular epidemiology of C. auris in Egypt. Four test strains were identified based on the ribosomal internal transcribed spacer (ITS) region sequence and phylogenetic analysis. Antifungal susceptibility was determined using the VITEK 2 system. Molecular analysis of ERG11, ERG3, FKS1, and FKS2 was used to identify mutations associated with antifungal resistance. The four test strains were identified as C. auris. Evolutionary analysis was conducted, and sequences of ITS regions were submitted to GenBank. The mutations Y132F in ERG11 and F635Y in FKS2 were identified, which are known to confer resistance to azoles and echinocandins, respectively. The emergence of C. auris in Egypt represents a public health concern. Hospitals should implement strict infection control measures to prevent its spread. Effective treatment guidelines and ongoing monitoring of antifungal resistance are essential to combat this emerging pathogen.
The influence of body composition on the survival of patients with metastatic clear cell renal carcinoma (mccRCC) treated with nivolumab (nivo) + ipilimumab (ipi).
545 Background: Over the last decade, immune checkpoint therapy (ICT) has become the cornerstone of first-line treatment for mccRCC. Despite the widespread use, there is heterogeneity in tumor response to ICT, and there is growing interest in how host factors modulate the tumor microenvironment. Recent studies in patients with mccRCC and other malignancies suggest that ICT may be more effective in patients with higher body mass index (BMI). Since BMI is an imperfect surrogate for distinct compartments of adipose tissue and muscle, we investigated the influence of body composition on outcomes with first-line (1L) nivo + ipi in patients with mccRCC. Methods: A retrospective analysis was conducted on patients with mccRCC at MD Anderson Cancer Center from June 2015 to Dec 2021 who received nivo + ipi as 1L treatment for advanced or mccRCC. Clinical data including demographics, BMI, and IMDC risk score were collected. Body composition was measured using an AI segmentation tool at the L3 vertebra from a pre-treatment CT scan obtained within 45 days of starting nivo + ipi. Efficacy endpoints of interest were time to treatment discontinuation (TTD), progression-free survival (PFS) and overall survival (OS). We constructed flexible multivariable Cox regression models guided by directed acyclic graphs to flexibly model the association of treatment outcomes with body composition measures as continuous variable, including nonlinear terms as cubic splines, and adjusting for IMDC risk and sarcomatoid dedifferentation as confounders. Results: 209 patients received 1L nivo + ipi (78.5% male, median age of 61 years, 59.3% and 32.5% IMDC intermediate- and poor-risk). Increasing skeletal muscle mass (SMMi) was associated with inferior PFS (HR 1.52, 95% CI 1.01 - 2.31 for 1-unit increase), whereas BMI and adiposity measures were not associated with PFS. Body composition measures were not significantly associated with OS, yet noteworthy trends were observed for visceral adiposity (VATi, HR 0.69, 95% CI 0.42 - 1.15 for 1-unit increase) and SMMi (HR 1.22, 95% CI 0.72 - 2.07). Conclusions: In a large cohort of patients with mccRCC, skeletal muscle mass was surprisingly associated with inferior PFS on 1L nivo + ipi. These results build upon conflicting body composition studies in mccRCC and suggest that future studies should investigate how skeletal muscle influences the tumor microenvironment.
Real-world persistence and adherence to relugolix (REL) in US patients with nonmetastatic (nm) vs metastatic (m) prostate cancer (PC).
88 Background: REL is the only oral androgen deprivation therapy (ADT) for patients (pts) with PC, offering an alternative to long-acting injectable/implantable formulations. Intermittent ADT is often used in pts with biochemically recurrent nmPC, whereas continuous ADT is the backbone of treatment (Tx) for pts with mPC. Given potential differences associated with adherence to an oral ADT, we assessed Tx adherence and persistence stratified by presence of metastases in pts with PC treated with REL. We hypothesized REL adherence would be high in both cohorts while persistence would be shorter in pts with nmPC vs mPC. Methods: A retrospective cohort study was conducted using the Medicare fee-for-service claims database (Dec 2019–Dec 2023). Adult males with >1 claim for PC who filled ≥2 REL prescriptions and had continuous Medicare coverage ≥1 year before and ≥3 months (mo) following REL initiation (index), when claims for metastatic diagnosis could be identified, were included. Pts were categorized into nmPC vs mPC cohorts. Persistence on REL was measured from time of Tx initiation (first pharmacy claim) to discontinuation (earliest of: switch to a different ADT, Tx gap ≥60 days between REL claims, death, or end of follow-up). REL adherence was measured using proportion of days covered (PDC) for pts persistent through fixed time periods (6- and 12-mo). PDC was defined as the percentage of individual days that pts had access to REL (based on prescriptions filled and days supplied). “Adherent” was defined as PDC of ≥80%. Results: The study included 5274 pts initiating REL; mean (SD) age was 75 (±7) years; 32% had mPC. Follow-up was similar in pts with nmPC and mPC (Table). Persistence on REL was shorter for nmPC vs mPC (median, 7 vs 9 mo; log-rank P <0.001). Across both cohorts, the vast majority of pts had PDC ≥80% (nmPC, 95%; mPC, 94%). Of those persistent at 6 mo, 95% across both cohorts had PDC ≥80%. Of those persistent at 12 mo, 97% had PDC ≥80% (nmPC, 98%; mPC, 96%). Conclusions: In this real-world study, among pts with PC who persisted on REL,high treatment adherence was observed, regardless of disease state (nmPC and mPC). Pts with mPC persisted on REL therapy longer compared to those with nmPC (median 9 vs 7 mos). Further research is needed to understand what other characteristics are associated with persistence on REL. Total(N=5274) nmPC with REL(n=3603) mPC with REL(n=1671) Follow-up (mo), mean ± SD [median] 16 ± 9 [15] 16 ± 9 [14] 16 ± 9 [15] Persistence on therapy (mo), mean ± SD [median] 10 ± 7 [7] 9 ± 7 [7] 11 ± 8 [9] Overall PDC, mean ± SD [median] 96 ± 10 [99] 97 ± 10 [99] 96 ± 11 [98] Overall PDC ≥80%, n (%) 4990 (95) 3424 (95) 1566 (94) Pts with ≥6 mo of persistence, n 3870 2617 1253 PDC ≥80% at 6 mo, n (%) 3676 (95) 2486 (95) 1190 (95) Pts with ≥12 mo of persistence, n 1830 1131 699 PDC ≥80% at 12 mo, n (%) 1775 (97) 1104 (98) 671 (96)
Erratum: Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors
Efficacy of neoadjuvant/induction (NAC) chemotherapy in nonmetastatic muscle-invasive bladder cancer treated with chemoradiotherapy (CRT): A systematic review and meta-analysis.
814 Background: Neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) is the established standard for nonmetastatic muscle-invasive bladder cancer (MIBC). However, bladder-sparing approaches using chemoradiotherapy (CRT) offer comparable outcomes. While NAC has proven beneficial before RC, its value prior to CRT remains uncertain. This systematic review and meta-analysis aimed to evaluate the impact of NAC on outcomes in patients undergoing CRT for bladder preservation. Methods: A comprehensive search of PubMed, Embase, and Cochrane databases was conducted to identify studies comparing NAC plus CRT versus CRT alone in MIBC. Both randomized controlled trials (RCTs) and observational studies were eligible. Studies with overlapping populations or non-English publications were excluded. Heterogeneity was assessed with I² statistics, and all analyses were performed using random-effects models in Review Manager 5.4.1. The study was registered in PROSPERO (CRD42024590258). Results: Four observational studies, encompassing 3,354 patients, were included as no RCTs met the inclusion criteria. NAC was administered to 656 patients (19.5%). Median follow-up ranged from 15.9 to 74.4 months. All patients in the NAC group received platinum-based chemotherapy (MVAC, ddMVAC, GC, or CMV). Concurrent CRT regimens included cisplatin, gemcitabine, or mitomycin with radiotherapy. No significant difference in overall survival was observed between NAC + CRT and CRT alone (HR = 0.99, 95% CI 0.87–1.13, p = 0.89, I² = 0%). Disease-free survival data were available from two studies, showing no significant difference (HR = 1.07, 95% CI 0.57–2.01, p = 0.82, I² = 39%). All included studies had a serious risk of bias, mainly due to confounding and selection bias, as assessed by the ROBINS-I tool. The overall certainty of the evidence was rated as very low using the GRADE framework. Conclusions: Our analysis found no survival benefit from adding NAC to CRT in patients with MIBC. However, the quality of the evidence is very low, largely due to the retrospective nature of the data. Further randomized clinical trials are needed to clarify the role of NAC in bladder preservation strategies.
All-implanted lateral β-Ga2O3 MOSFET devices realized on semi-insulating (-201) β-Ga2O3 substrates
In this work, we report on the fabrication of all-implanted β-Ga2O3 metal-oxide-semiconductor field-effect transistor (MOSFET) devices on semi-insulating (-201) β-Ga2O3 substrates. Through the use of multiple energy Si+ implantation and subsequent annealing, we were able to achieve high activation efficiencies up to 87% allowing to realize the active transistor channel and Ohmic contact regions with electrical properties comparable to homoepitaxial layers grown by metal-organic chemical vapor deposition. The fabricated β-Ga2O3 MOSFET devices featured excellent current modulation with on/off current ratios up to 109, maximum drain current densities of 180 mA/mm, and specific on-resistances of 1.5 mΩcm2. Furthermore, breakdown measurements in air of the non-field-plated MOSFET devices with a gate-to-drain distance of 2 μm showed a catastrophic breakdown at 332 V, which equals an average breakdown strength of 1.7 MV/cm. The outcome of this work emphasizes the high potential of this all-implantation approach for fabricating high-performing Ga2O3-based electronic devices for next-generation power electronics applications without the need of sophisticated high-quality epitaxial growth.
HybridBranchNetV2: Towards reliable artificial intelligence in image classification using reinforcement learning
Many artificial intelligence (AI) algorithms struggle to adapt effectively in dynamic real-world scenarios, such as complex classification tasks and object relationship extraction, due to their predictable but non-adaptive behavior. This paper introduces HybridBranchNetV2, an optimized hybrid architecture designed to address these challenges. The key novelty of our approach lies in the integration of reinforcement learning for adaptive feature extraction and the use of graph-based techniques to analyze object relationships in complex environments. By dynamically adjusting feature extraction based on feedback from the environment, the model improves adaptability, while graph-based methods allow for a more comprehensive analysis of object relationships. Our extensive evaluations demonstrate that HybridBranchNetV2 achieves average 91.75% accuracy over four different challenging datasets. In particular, a 14% improvement obtained on the Visual Genome dataset and ImageNet 1K compared to the original HybridBranchNet model. Additional testing on CIFAR, Flowers, and ImageNet datasets revealed improvements of 6%, 1%, and 6%, respectively. These advancements not only enhance classification accuracy but also ensure efficient computation, making HybridBranchNetV2 suitable for real-time applications with minimal risk of overfitting. The proposed framework demonstrates significant improvements in adaptability, performance, and computational efficiency, addressing critical limitations in current AI models.
Optimal scheduling of solar powered EV charging stations in a radial distribution system using opposition-based competitive swarm optimization
Real-world analysis of pembrolizumab utilization and characteristics of patients being prescribed treatment in early stage RCC.
480 Background: In the United States, adjuvant pembrolizumab was approved on November 17, 2021, for patients with RCC with intermediate-high (T2N0M0-G4, T3N0M0, any grade) or high risk (T4, any grade; N+, any T, any grade; and M1NED patients) of recurrence following nephrectomy. This study aims to assess adoption of adjuvant pembrolizumab in routine practice and demographic and clinical characteristics of post nephrectomy RCC patients who received this therapy. Methods: This retrospective study included adult patients with non-metastatic localized RCC who underwent nephrectomy between November 17, 2021, and December 31, 2022, and were seen in the U.S. Oncology Network. Patients were excluded if they were treated for other documented primary cancer diagnoses or enrolled in clinical trials. Descriptive analyses were conducted to evaluate demographic, clinical, and treatment characteristics overall, and for patients who received adjuvant pembrolizumab monotherapy and those who did not. Multivariate logistic regression was used to identify factors associated with adjuvant pembrolizumab use. Results: In total, 178 patients were included. The mean age was 62 years (SD 11.8), with a majority being male (66.3%, n=118), and a median follow-up of 7.9 months (Q1,Q3: 4.1,9.8). The majority had intermediate-high risk (n=86, 57.5%), clear cell (cc) RCC (n=147, 82.6%) and received adjuvant pembrolizumab monotherapy (n=118, 66.3%). Among those who received adjuvant pembrolizumab, 90.7% had ccRCC, 62.5% were intermediate-high risk (T2N0G4: 8 (55.1%), T3N0 All Grades: 53 (44.9%)), 27.5% were N+ with a median follow-up of 8.3 (Q1, Q3: 6.0, 10.1) months. Median time to the start of adjuvant pembrolizumab post nephrectomy was 1.6 months (Q1, Q3: 1.3,2.1). The median time to treatment discontinuation was 11.5 months (Q1, Q3: 9.0, 11.5) (the recommended duration of treatment for adjuvant pembrolizumab is: 12 months at 17 cycles at 200mg/ Q3W or 9 cycles at 400mg/Q6W). Multivariate analysis showed that patients with non ccRCC histology were 93% less likely (p-value: <0.0001) and those whose with first oncologist visit >=2 months post nephrectomy were 60% less likely (p-value:0.035) to receive adjuvant pembrolizumab treatment. Conclusions: This study demonstrated notable uptake of adjuvant pembrolizumab among post-nephrectomy RCC patients in this community setting following FDA approval. RCC histology and the timing of oncologist visits post nephrectomy were significant factors influencing the receipt of adjuvant pembrolizumab. Future research should focus on examining referral patterns, and identifying the drivers and barriers to treatment adoption, with the goal of developing strategies to enhance its integration. Additionally, future research may explore long-term outcomes and real-world effectiveness of adjuvant pembrolizumab.
Application of radiomics as a risk stratification tool in node positive penile cancer.
3 Background: The risk level of lymph node metastasis in penile cancer is determined using the Graafland criteria which determines how patients are treated. These imaging-based criteria have critical implications on patient care yet have not been extensively validated. The purpose of this study was to validate the Graafland criteria and to assess the use of radiomics analysis of CT scans to standardize risk stratification. Methods: Thirty-eight patients with squamous cell penile cancer with CT scans prior to regional lymphadenectomy were included in this retrospective cohort. Patients with prior chemotherapy for PSCC or any inguinal and pelvic radiotherapy were excluded. All CT scans were performed using IV contrast with axial slice thickness of 3mm. CT scans were analyzed by two experienced oncologic radiologists using Graafland criteria. The largest inguinal lymph node in each patient was segmented and radiomics features were extracted and compared to pathologic evidence of high-risk disease. 308 radiomic features were identified. Features with poor predictive value (i.e. AUC <0.5) were excluded. Pearson’s correlation coefficient was used to find the clusters of features (absolute value of correlation of ≥0.95), and the most predictive feature of each cluster was selected.199 features with best predictive value were selected for analysis. Two logistic regressions were performed using stepwise selection and LASSO approach. Results: In 38 subjects, 16 of 38 patients were identified as harboring lymph node metastasis on surgical pathology. Applying Graafland criteria had an inter-reader concordance of 89.5% (34/38), an accuracy of 86.8% (95%CI: 71.9% - 95.6%); AUC: 0.869 (95% CI: 0.758– 0.981); Sensitivity 87.5%; and Specificity 86.4% in predicting high-risk disease. CT radiomics analysis yielded a model including two features F54 (compactness) and F279 (3D wavelet_P1_L2_C1) which is a multi-order texture-based feature. The logistic regression with stepwise selection included two features (F54 and F279) and had an (AUC = 0.921 ± 0.096) after five-fold cross validation. Conclusions: Graafland criteria accurately predicted the presence of high-risk nodal disease on pre-operative CT scans when assessed by expert radiologists. Radiomic analysis shows promise in further refining and standardizing the detection of high-risk nodal disease with the advantage in ease of training and/or clinical application.
Genomic alterations and their pathologic responses in high-risk localized prostate cancer (HRLPC) in subprotocol 1 of the Genomic Umbrella Neoadjuvant study (GUNS).
403 Background: GUNS (NCT04812366) is a multicenter adaptive phase II trial evaluating 24 weeks of biomarker-selected, neoadjuvant androgen receptor pathway inhibitor (ARPI) combination therapies on depth of pathologic response (complete response [pCR] or <5 mm minimal residual disease [MRD]) in HRLPC. After 8 weeks of LHRHa + apalutamide (APA), participants are assigned to 1 of 4 sub-protocols (SP) combining 16 weeks of an ARPI doublet with drugs defined by specific genomic alterations (e.g. SP-2, docetaxel for RB1 , PTEN , TP53 loss; SP-3, niraparib for DNA-repair def ; SP-4, atezolizumab for mismatch-repair def ). SP-1 randomises men without these aggressive genomic alt and includes those that enhance AR activity (ETS fusions, FOXA1 , SPOP ) to either SP-1a (LHRHa + APA) or SP-1b (LHRHa + APA + abiraterone acetate/prednisone). SP-1 tests the hypothesis that ARPI triplet intensification, in cancers with AR-associated genomic alt , will increase depth of pathologic response. Methods: From 9/2021 to 8/2024, GUNS enrolled 95 and 30 men at University of BC and Toronto, respectively. Diagnostic biopsies underwent Tempus’ CLIA-certified 648-gene panel DNA sequencing (seq) and whole-transcriptome RNA-seq. This analysis focuses on 46 men enrolled to the 1 st stage of SP-1 who completed neoadjuvant therapy and surgery. Results: DNA-seq from 105/125 patients reveals a genomic landscape dominated by AR-associated alterations ( 36% ETS fusion, 23% FOXA1, 13% SPOP ). Other frequently altered genes were TP53 (14%), PTEN (12%), and BRCA2 (9%). Transcriptomes largely cluster in alignment with ETS fusions and SPOP status. ETS fusions were associated with PCS2-luminal-subtype and decreased proliferative signatures, whereas most other genomic alt were associated with PCS1-luminal-subtype. AR signatures associated with SPOP and FOXA1 mutations but not ETS fusions. 46 men, equally balanced for high-risk features and genomic alt , were randomized to SP-1a or SP-1b. Undetectable pre-surgery PSA levels trended higher in SP-1b (16/23) vs. SP-1a (11/23), but was not statistically significant (p = 0.12). While there were no pCR, MRD rates were significantly higher in SP-1b compared to SP-1a (43% vs 13%, p=0.012, odds ratio = 5.9). Degenerative scores (morphologic indicators of treatment stress) also averaged higher in SP-1b vs. SP-1a. Positive margin (17%) and lymph node (35% vs 26%) status were similar in both arms. Although genomic PTEN alt were assigned to SP-2, 7 patients in SP-1 were found to be PTEN neg by IHC and 6 were non-MRD; PTEN-IHC neg trended more common in non-MRD (21%) than MRD (8%) cases. Conclusions: SP-1 associated genomic alt (ETS fusion, FOXA1, SPOP) are the most frequent alterations in GUNS. Significantly higher rates of MRD in SP-1 patients treated with an ARPI triplet vs. doublet are of interest and support further evaluation with 2 nd stage expansion. Clinical trial information: NCT04812366 .
Assessing practice gaps and challenges for immunotherapy integration in treatment of metastatic urothelial carcinoma.
694 Background: The approval of pembrolizumab with enfortumab vedotin in the first-line setting has shifted the treatment paradigm for patients with metastatic urothelial carcinoma (mUC). However, integrating these novel therapies into clinical practice can be challenging for health care providers (HCPs). To better understand real-world challenges and barriers for integrating immunotherapy in routine practice, we surveyed providers across community-based oncology settings. Methods: Between 02/2024 and 04/2024, multidisciplinary (MDT) oncology team members (N = 60) across the US were surveyed to assess providers' current practices and challenges regarding biomarker testing, immunotherapy use, and multidisciplinary coordination in mUC care. Teams then participated in a network-wide workshop to develop action plans for improving mUC care. Results: HCPs reported ongoing challenges in integrating novel therapies in clinical practice, including individualizing treatment plans and sequencing (28%), keeping up with clinical evidence (24%), and differentiating available immunotherapy and combination regimens (14%). Additionally, HCPs reported challenges in providing patient-centered supportive care (12%) and engaging patients in shared decision-making (10%). Most HCPs routinely tested for PD-L1 (82%), HER2 expression (63%) and alteration (55%), and FGFR (62%) , and <50% tested PIK3CA and CDKN2A alterations. While HCPs felt confident in applying the latest guidelines to treatment selection (62%), only 45% of cisplatin-ineligible patients were reported to have received approved first-line immunotherapy combination in the metastatic setting. Most HCPs felt confident recognizing and managing immune-related adverse events (64%) and reported that only 15% of patients required treatment discontinuation due to adverse events. Only 21% of HCPs were fully satisfied with MDT coordination/communication and believed that improving MDT collaboration (33%) and provider education on integrating immunotherapy and combination approaches (31%) would most improve mUC care. After participating in a network-wide workshop, teams developed action plans including improving MDT coordination, standardizing and streamlining biomarker testing, and increasing education on treatment sequencing guidelines. Following integration of these action plans, 100% of HCPs reported improved/increased alignment with evidence-based guidelines. Additionally, HCPs reported increasing provider education on integrating immunotherapy and combination therapies into practice (71%) and improving MDT collaboration (71%). Conclusions: These data and actionable insights can inform future targeted initiatives to improve integration of evidence-based immunotherapy and combination targeted agents into practice for patients with mUC.
Terahertz near-zero reflection modulator based on cascaded electrical length reconfiguration
Return loss is a core indicator of module connectivity performance in integrated communication systems. Reflections from the modulation device can cause power fluctuations, leading to excessive amplitude noise affecting the system's signal-to-noise ratio. To solve the problem of high return loss in existing terahertz amplitude modulation techniques, this paper proposes a near-zero reflection terahertz modulator based on an electrical length reconfiguration cascade. The ON-OFF effect of the modulator is achieved through the cascade's electrical length reconstruction, and the reflections are effectively suppressed from the ON state to the OFF state. Experimental results demonstrate that the proposed modulator achieves a broadband low-reflection effect in the 170–260 GHz band, with a Voltage Standing Wave Ratio (VSWR) of less than 1.5 over a bandwidth of 60 GHz and an optimal VSWR of 1.1. It has the potential to support high-speed response as well as the large-capacity, high-rate data transmission. Accordingly, the proposed modulator offers a promising solution for the design of high-performance terahertz modulators and multi-channel integrated terahertz communication systems.
Preferential apical infection of Caco-2 intestinal cell monolayers by SARS-CoV-2 is associated with damage to cellular barrier integrity: Implications for the pathophysiology of COVID-19
SARS-CoV-2 can infect different organs, including the intestine. In an in vitro model of Caco-2 intestinal cell line, we previously found that SARS-CoV-2 modulates the ACE2 receptor expression and affects the expression of molecules involved in intercellular junctions. To further explore the possibility that the intestinal epithelium can serve as an alternative infection route for SARS-CoV-2, we used a model of polarized monolayers of Caco-2 cells (or co-cultures of two intestinal cell lines: Caco-2 and HT29) grown on the polycarbonate membrane of Transwell inserts, inoculated with the virus either in the upper or lower chamber of culture to determine the tropism of the virus for the apical or basolateral pole of these cells. In both polarized Caco-2 cell monolayers and co-culture Caco-2/HT29 cell monolayer, apical SARS-CoV-2 inoculation was found to be much more effective in establishing infection than basolateral inoculation. In addition, apical SARS-CoV-2 infection triggers monolayer degeneration, as shown by histological examination, measurement of trans-epithelial electrical resistance, and cell adhesion molecule expression. During apical infection, the infectious viruses reach the lower chamber, suggesting either a transcytosis mechanism from the apical side to the basolateral side of cells, a paracellular trafficking of the virus after damage to intercellular junctions in the epithelial barrier, or both. Taken together, these data indicate a preferential tropism of SARS-CoV-2 for the apical pole of the human intestinal tract and suggest that infection via the intestinal lumen leads to a systemic infection.
A robust deep learning framework for multiclass skin cancer classification
Evaluating survival post-7 mo PSA response, stratified by response, disease extent, and intermittent vs. continuous ADT in mHSPC: The S9346 trial.
268 Background: A decline in prostate-specific antigen (PSA) following androgen deprivation therapy (ADT) is a well-established prognostic marker in metastatic hormone-sensitive prostate cancer (mHSPC). While S9346 trial found intermittent ADT (IAD) to be not non-inferior to continuous ADT (CAD) in mHSPC, de-intensification strategies are being considered for patients with complete PSA response. We hypothesize that IAD has different treatment effect in men with partial and complete PSA response. Methods: In the phase 3 S9346 trial men with mHSPC were randomized to IAD and CAD, if they had PSA ≤ 4.0 ng/ml after 7 months (PSA-7mo) of treatment with ADT and bicalutamide. We evaluated the association of complete PSA-7mo response (CR, PSA ≤ 0.2 ng/ml) and partial PSA -7mo response (PR, PSA 0.3-4 ng/ml) with subsequent overall survival (OS) in patients with mHSPC treated with either IAD or CAD in S9346 trial using Cox regression. We evaluated association of the disease extent and OS, using Cox regression: minimal disease defined as metastasis confined to the spine, pelvic bones, or lymph nodes; and extensive disease defined as metastasis involving ribs, long bones, or visceral organs. Results: The analysis included 1523 patients from the S9346 trial. In the IAD arm (n=763), 483 men (63%) achieved CR and 280 (37%) had PR. In the CAD arm (n=760), 473 men (62%) achieved CR and 287 (38%) had PR. A PSA-7mo CR was associated with significantly improved OS compared to PR (HR 0.57, 95% CI 0.51-0.65, p<0.0001). Extensive disease was associated with worse OS compared to minimal disease (HR 1.3, CI 1.15-1.47, p<0.0001). However, the relative treatment effect of IAD remained consistent across these subsets of patients: IAD vs CAD in subset of patients with CR HR 1.15, 95% CI 0.96-1.39; and in patients with PR HR 1.14, 95% CI 0.98-1.34. There was no statistically significant pairwise interaction between PSA response, extent of disease, and IAD vs. CAD in the multivariate OS Cox analysis (all p≥ 0.20). Conclusions: This study reaffirms the prognostic significance of a PSA-7mo CR and disease extent. IAD had the same relative treatment effect for those with a PSA CR vs. PR. These findings indicate that IAD is not an optimal therapy even in patients with good prognostic baseline clinical features and on treatment response. Clinical trial information: NCT00002651 . Multivariate Model (n=1523) Hazard Ratio 95% CI p-value CR vs. PR PSA-7mo response 0.57 (0.51, 0.65) <0.0001 Extensive vs. Minimal Disease 1.30 (1.15, 1.47) <0.0001 IAD vs. CAD 1.14 (1.02, 1.29) 0.027 IAD Arm Subset Median OS (95% CI) In months CAD Arm Subset Median OS (95% CI) In months PSA CR, ext. disease (n=228) 71 (61,83) PSA CR, ext. disease (n=193) 71 (58, 82) PSA CR, min. disease (n=255) 77 (66, 95) PSA CR, min. disease (n=280) 92 (85, 103) PSA PR, ext. disease (n=147) 43 (35, 53) PSA PR, ext. disease (n=167) 44 (36, 50) PSA PR, min disease (n=133) 43 (37, 55) PSA PR, min disease (n=120) 60 (43, 76)
Adrenal androgens and overall survival (OS) in men with castration-resistant prostate cancer (CRPC) treated with enzalutamide without (ENZ) or with abiraterone and prednisone (ENZ/AAP) (Alliance).
230 Background: DHEA, testosterone (T) and androstenedione (AD) are adrenal androgens that can drive CRPC. HSD3B1 encodes for 3β-hydroxysteroid dehydrogenase-1 (3βHSD1) and has 2 common missense-encoding germline variants: the more active adrenal-permissive allele and the less active adrenal-restrictive allele that are associated with greater and lesser non-gonadal androgen biosynthesis from DHEA. A single adrenal-permissive HSD3B1 (1245C) allele is sufficient to confer more rapid development of CRPC and homozygous inheritance (about 7-10% of men) is the most common monogenic link to prostate cancer mortality. Alliance A031201 (NCT01949337) is a phase 3 trial of ENZ versus ENZ/AAP for metastatic CRPC. This analysis combines clinical outcomes associated with adrenal androgens and HSD3B1 as the gene encoding the enzyme that uses dehydroepiandrosterone (DHEA). Methods: Germline DNA was genotyped for HSD3B1 in 929 men from A031201 (469 ENZ and 460 ENZ/AAP). Baseline DHEA, T and AD were assessed in 922 men (464 ENZ and 458 ENZ/AAP) using mass spectrometry. The Cox proportional hazards model was used to determine the prognostic significance of DHEA, T and AD categorized as tertiles in predicting OS. Results: In the combined treatment arms, median (95% CI) OS for men in low, medium and high DHEA tertiles was 27 (25, 31), 36 (33, 42) and 39 (37, 47) months (Table). In the ENZ arm, men with inheritance of 0, 1 and 2 adrenal-permissive alleles had median OS of 34 (30, 39), 34 (29, 39) and 28 (23, 37) months. Conclusions: DHEA is the most informative adrenal androgen. Men with the lowest tertile for this substrate of 3βHSD1 have the shortest OS. These data are consistent with prior analyses demonstrating poor prognosis for men with low adrenal androgens. Outcomes for men homozygous for the adrenal-permissive HSD3B1 allele treated with ENZ are consistent with prior retrospective studies. Overall survival and adrenal androgens. Serum Androgen Median OS in months (95% CI) Multivariable Hazard Ratio (95% CI) DHEA 1 st Tertile (Low) DHEA 2 nd Tertile (Medium) DHEA 3 rd Tertile (High) 27 (25, 31)36 (33, 42)39 (37, 47) AC vs. AA 0.97 (0.82,1.14)CC vs. AA 1.08 (0.81,1.44)DHEA: Med vs High 1.17 (0.97,1.42)DHEA: Low vs. High 1.65 (1.37,2.00) AD 1 st Tertile (Low) AD 2 nd Tertile (Medium) AD 3 rd Tertile (High) 32 (27, 36)36 (34,43)34 (31, 39) AC vs. AA 0.96 (0.82,1.13)CC vs. AA 1.08 (0.81, 1.44)AD: Med. vs. High 0.89 (0.73,1.07)AD: Low vs. High 1.16 (0.97,1.40) T 1 st Tertile (Low) T 2 nd Terile (Medium) T 3 rd Tertile (High) 28 (26, 35)37 (34, 41)36 (32, 41) AC vs. AA 0.95 (0.81,1.12)CC vs. AA 1.07(0.80,1.43)T: Med vs. High 1.01 (0.83,1.22)T: Low vs. High 1.28 (1.06,1.54)
EPIC-B: Phase II trial of cemiplimab as first-line treatment in advanced penile carcinoma.
9 Background: Patients with locally advanced or metastatic penile squamous cell carcinoma (la/mPC) have a poor prognosis with very limited therapeutic treatment options. Standard of Care (SoC) treatment remains platinum-based combination chemotherapy with modest outcomes. Some patients are ineligible for chemotherapy and have very limited options for management. PDL1 is upregulated in 40–60% of PC, making a case for immunotherapy as a treatment for la/mPC. We describe the results from the EPIC-B trial, evaluating the efficacy and safety of cemiplimab as first line treatment in la/mPC. Methods: EPIC-B is a National Cancer Research Network badged single arm, multi-center phase II trial, in treatment naïve la/mPC. Patients received cemiplimab 350mg IV D1 every 3 weeks (Q3W) up to a total of 34 cycles. The primary end point was investigator assessed Clinical Benefit Rate (CBR) at 12 weeks using RECIST 1.1. The study was designed as an A’Hern (2001) study α=0.05 + power (1-β)=0.8 assuming 5% meeting the primary end point is a poor treatment (p0=0.05) and 25% is a good treatment (p1=0.25). Assuming a 10% drop out rate, 18 patients were recruited to test this hypothesis. Results: From November 2021, 18 patients from 11 UK sites were enrolled onto EPIC-B over 29 months. Median age was 72 years (range 44-88). Patients with ECOG 0-2 were allowed onto the trial, the majority having ECOG 1 or 2 (0=5%, 1=56% and 2=39%). 83% had metastatic disease (1 bone 5.6%, 1 liver 5.6%, 6 lung 33.3%). Median number of cycles was 4 (range 1-32) and median follow-up was 5.5 (IQR 2.3-8.1) months. At 12 weeks CBR was 38.9% (95%CI 20.3%, 61.4%) and Objective Response Rate (ORR) was 16.6% (95%CI 5.8%, 39.2%) with 3 partial response (PR) and 4 stable disease (SD). Over the full course of treatment 27.7% of patients showed a response to treatment including 1 complete response (1 CR, 4 PR) and 4 patients had SD as their best response. Median Progression Free Survival (PFS) was calculated to be 2.3 (95%CI 1.0, 3.8) months and median Overall Survival (OS) is currently estimated at 6.8 (95%CI 3.7, 9.8) months. For adverse events (AEs) of any grade, 31% were judged related to cemiplimab and for grade 3 AEs 26% were related, most common being infection (no G4 AEs were recorded). There were 2 grade 5 AEs, (cardiorespiratory event not related and toxic epidermal necrolysis related to treatment). 4 patients discontinued treatment due to toxicity, 2 related to cemiplimab (11%). Conclusions: Single agent cemiplimab as a first line treatment for la/mPC in the EPIC-B trial demonstrates efficacy with a generally manageable toxicity profile. This study adds to the evidence that single agent cemiplimab is a viable treatment for la/mPC patients for whom chemotherapy is not an option. Clinical trial information: 95561634.
Safety and efficacy of intravesical bacillus Calmette-Guerin instillation for superficial recurrence following bladder-sparing therapy of muscle invasive bladder cancer.
787 Background: Patients treated with bladder-preserving therapy for muscle-invasive bladder cancer are at risk of developing recurrent non-muscle-invasive bladder cancer. This study aims to evaluate the efficacy and adverse events of postoperative Bacillus Calmette-Guerin (BCG) instillation in patients with superficial recurrence following bladder-preserving therapy for muscle-invasive bladder cancer. Methods: We retrospectively analyzed 120 patients diagnosed with non-muscle-invasive bladder cancer who underwent transurethral resection followed by BCG instillation. The 19 patients with prior muscle-invasive bladder cancer were categorized as the NMIBC-M group, while the remaining 101 patients formed the NMIBC group. All patients completed a six-cycle BCG course. Results: Both groups showed no significant differences in baseline characteristics, except for the number of BCG instillations (15.5 vs. 9, p = 0.010). Overall survival, recurrence-free survival, metastasis, bladder preservation, and adverse event profiles were comparable between groups. However, patients in the group with prior muscle-invasive bladder cancer reported lower rates of urinary retention (28.7% vs. 0.0%, p = 0.017) and fever (30.7% vs. 5.3%, p = 0.044). Conclusions: Postoperative BCG instillation in patients with superficial recurrence following bladder-preserving therapy for muscle-invasive bladder cancer showed comparable efficacy and side effects to those without muscle-invasive bladder cancer history.
Enhanced stability and mobility of aligned In2O3 nanofiber field-effect transistors with Y2O3 passivation
Field-effect transistors (FETs) based on indium oxide (In2O3) nanofibers demonstrate significant potential for applications in next-generation electronic devices. However, In2O3 nanofiber FETs typically exhibit deteriorated electrical performance and bias stability due to the disordered arrangement of nanofibers and a high concentration of oxygen vacancy defects. In this study, In2O3 nanofibers were prepared by electrospinning, and the effects of nanofiber orientation and Y2O3 passivation on FET electrical performance were systematically investigated. The results indicate that after Y2O3 passivation, the aligned In2O3 nanofiber FETs exhibit enhanced electrical performance and superior positive bias stress and negative bias illumination stress stability. The Y2O3 passivation layer effectively prevents the penetration of external O2 and H2O molecules, while the diffusion of Y3+ into the back channel reduces oxygen vacancies, thereby improving device stability. When Al2O3 was employed as the dielectric layer, the electrical performance of aligned In2O3 nanofiber FET with Y2O3 passivation was further optimized, achieving a mobility of 18.2 cm2/V s and a subthreshold swing of 85 mV/dec. Meanwhile, the FET exhibits excellent environmental stability after 60 days of atmospheric exposure. This work provides a strategy for fabricating nanofiber-based FETs with high mobility and stability.